Intrinsic equity value per share declined to €6.33 by August 2024, with cash rising to €62.9m after the CG Oncology divestment. Malin plans a €45m capital return and remains focused on value creation in its investee companies.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.